



2006 Life Sciences

Life sciences leaders turn to WilmerHale for legal advice and business advantage. We provide incisive solutions to the business challenges facing biotechnology, pharmaceutical, healthcare and medical device companies at all stages of growth. For over four decades, we have represented life sciences clients in venture financings, public offerings, mergers and acquisitions, patent prosecution and portfolio development, licensing agreements and landmark collaborations, and have defended their innovations in critical patent litigation.



Counsel of Choice to Life Sciences Leaders...from Biotech to Medical Devices.

Venture Capital and PIPEs Financings

 TransMedics \$29,750,000 Third Round February 2006	 Intercept pharmaceuticals \$41,000,000 First Round May 2006	 XANTHUS PHARMACEUTICALS \$25,000,000 Second Round November 2006	 TetraPhase \$25,000,000 First Round August 2006	
 Adnexus Therapeutics \$27,000,000 Second Round June 2006	 U3 PHARMA €27,000,000 Third Round May 2006	 BioSphere Medical \$14,525,000 PIPEs Financing February 2006	 Aushon BioSystems \$7,800,000 First Round October 2006	 CODON DEVICES \$20,000,000 Second Round December 2006

Public Offerings and Rule 144A Placements

 emergent biosciences Initial Public Offering of Common Stock \$62,500,000 Counsel to Issuer November 2006	 Medtronic Rule 144A Placement of 1.50% Convertible Senior Notes due 2011 and 1.625% Convertible Senior Notes due 2013 \$4,400,000,000 Counsel to Issuer April 2006	 Alnylam PHARMACEUTICALS Public Offerings of Common Stock \$165,917,000 Counsel to Issuer February and December 2006	 Altus Initial Public Offering of Common Stock \$120,750,000 Counsel to Underwriters January 2006	 ACHILLION Initial Public Offering of Common Stock \$59,512,500 Counsel to Issuer October 2006	
 MILLENNIUM Public Offering of 2.25% Convertible Senior Notes due 2011 \$250,000,000 Counsel to Issuer October 2006	 LeMaitre VASCULAR Initial Public Offering of Common Stock \$38,500,000 Counsel to Underwriters October 2006	 Labopharm Initial Public Offering of Common Stock \$101,200,000 Counsel to Underwriters May 2006	 COLLAGENEX PHARMACEUTICALS Public Offering of Common Stock \$45,500,000 Counsel to Issuer November 2006	 STAGE Public Offering of Common Stock \$56,336,000 Counsel to Issuer June 2006	 ALEXION pharmaceuticals Public Offering of Common Stock \$148,350,000 Counsel to Underwriters November 2006

Strategic Alliances and Collaborations

 ZIOPHARM Oncology Acquisition from Baxter Healthcare of clinical-stage anti-cancer agent program	 MOMENTA Alliance with Sandoz to develop complex generic and follow-on biotechnology drugs	 NOVARTIS License by Novartis Pharma to Cerimon of Simulect* antibody for the treatment of inflammatory bowel disease	 idera PHARMACEUTICALS Collaboration with Merck to develop vaccines incorporating toll-like receptor agonists	 Syntonix PHARMACEUTICALS, INC. Strategic alliance with Biovitrum for long-acting hemophilia B product	 Bristol-Myers Squibb Licensing advice for drug discovery and development agreements
 AVEO PHARMACEUTICALS License from Kirin Brewery of clinical-stage cancer product	 LABORATORIES INC BrainTree License to Schering-Plough of MiraLAX* over-the-counter gastrointestinal products	 Infinity PHARMACEUTICALS Alliance with MedImmune for novel small molecule cancer drugs	 Cephalon deliver more Licensing advice in connection with settlements of Provigil* generic patent infringement litigation	 PTC PHARMACEUTICALS Collaboration with Schering-Plough for the development of hepatitis C virus drugs	

Mergers and Acquisitions

 GlycoFi acquisition by Merck \$400,000,000 June 2006	 domantis acquisition by GSK £230,000,000 January 2007	 SAVIENT PHARMACEUTICALS, INC. sale of oral liquid pharmaceuticals business to Close Brothers Private Equity \$176,000,000 August 2006	 WebMD acquisition of Subimo \$60,000,000 December 2006	 PAREXEL acquisition of California Clinical Trials Medical Group and Behavioral and Medical Research \$65,000,000 November 2006	 BD acquisition of GeneOhm Sciences \$230,000,000 February 2006
 ThermoFisher SCIENTIFIC acquisition of Cohesive Technologies Undisclosed December 2006	 HMS Holdings Corp. acquisition of the Benefits Solutions Practice Area division of Public Consulting Group \$100,000,000 September 2006	 IDX acquisition by GE Healthcare \$1,200,000,000 January 2006	 Infinity PHARMACEUTICALS acquisition of Discovery Partners \$162,500,000 September 2006	 Lifeline acquisition by Philips Electronics \$750,000,000 March 2006	

wilmerhale.com

WILMER CUTLER PICKERING HALE AND DORR LLP

Wilmer Cutler Pickering Hale and Dorr LLP is a Delaware limited liability partnership. Our United Kingdom offices are operated under a separate Delaware limited liability partnership of solicitors and registered foreign lawyers regulated by the Law Society of England and Wales. In Beijing, we are registered to operate as a Foreign Law Firm Representative Office. WilmerHale principal law offices: 60 State Street, Boston, Massachusetts 02109, +1 617 526 6000; 1875 Pennsylvania Avenue, NW, Washington, DC 20006, +1 202 663 6000. Prior results do not guarantee a similar outcome.